CA2908832C - Inhibitors of metastasis - Google Patents

Inhibitors of metastasis Download PDF

Info

Publication number
CA2908832C
CA2908832C CA2908832A CA2908832A CA2908832C CA 2908832 C CA2908832 C CA 2908832C CA 2908832 A CA2908832 A CA 2908832A CA 2908832 A CA2908832 A CA 2908832A CA 2908832 C CA2908832 C CA 2908832C
Authority
CA
Canada
Prior art keywords
peptide
seq
mans
marcks
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2908832A
Other languages
English (en)
French (fr)
Other versions
CA2908832A1 (en
Inventor
Indu Parikh
Kenneth B. Adler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Biomarck Pharmaceuticals Ltd
Original Assignee
North Carolina State University
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University, Biomarck Pharmaceuticals Ltd filed Critical North Carolina State University
Publication of CA2908832A1 publication Critical patent/CA2908832A1/en
Application granted granted Critical
Publication of CA2908832C publication Critical patent/CA2908832C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
CA2908832A 2013-04-05 2014-04-07 Inhibitors of metastasis Active CA2908832C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05
US61/808,966 2013-04-05
PCT/US2014/033206 WO2014165853A1 (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Publications (2)

Publication Number Publication Date
CA2908832A1 CA2908832A1 (en) 2014-10-09
CA2908832C true CA2908832C (en) 2023-01-24

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908832A Active CA2908832C (en) 2013-04-05 2014-04-07 Inhibitors of metastasis

Country Status (19)

Country Link
US (4) US9408886B2 (https=)
EP (1) EP2981279B1 (https=)
JP (1) JP6449849B2 (https=)
KR (1) KR102191695B1 (https=)
CN (1) CN105517562B (https=)
AU (1) AU2014247979B2 (https=)
BR (1) BR112015025398A2 (https=)
CA (1) CA2908832C (https=)
DK (1) DK2981279T3 (https=)
ES (1) ES2714863T3 (https=)
HU (1) HUE043971T2 (https=)
IL (1) IL241937B (https=)
MX (1) MX363077B (https=)
PL (1) PL2981279T3 (https=)
PT (1) PT2981279T (https=)
RU (1) RU2681213C2 (https=)
SG (2) SG11201508249WA (https=)
WO (1) WO2014165853A1 (https=)
ZA (1) ZA201508010B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043971T2 (hu) * 2013-04-05 2019-09-30 Biomarck Pharmaceuticals Ltd Egy fûtõrendszer mûködtetési eljárása, fûtõrendszer és felhasználásai
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂
EP4475866A4 (en) * 2022-02-07 2026-02-25 Park Strategic Ventures Llc Peptides and their methods of use in the treatment of eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
WO2003030827A2 (en) 2001-10-05 2003-04-17 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
EP2399599A3 (en) 2005-01-20 2012-04-18 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
WO2006086681A2 (en) 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
CN101516190B (zh) 2006-07-26 2014-06-11 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
WO2008127355A2 (en) * 2006-10-06 2008-10-23 Celtaxsys, Inc. Chemorepulsion of cells
JP2010508512A (ja) 2006-10-27 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 転移性結腸直腸癌のアッセイ
WO2009062128A2 (en) 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2011079015A1 (en) 2009-12-21 2011-06-30 The Regents Of The University Of California Rgd-containing cyclic peptides
JP6225104B2 (ja) * 2011-04-08 2017-11-01 タフツ メディカル センター インコーポレイテッドＴｕｆｔｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ，Ｉｎｃ． ペプデューシンの設計および使用
HUE043971T2 (hu) * 2013-04-05 2019-09-30 Biomarck Pharmaceuticals Ltd Egy fûtõrendszer mûködtetési eljárása, fûtõrendszer és felhasználásai

Also Published As

Publication number Publication date
DK2981279T3 (en) 2019-03-25
CA2908832A1 (en) 2014-10-09
AU2014247979A1 (en) 2015-10-29
EP2981279B1 (en) 2018-12-19
SG11201508249WA (en) 2015-11-27
NZ712955A (en) 2021-03-26
SG10201708125PA (en) 2017-11-29
RU2681213C2 (ru) 2019-03-05
MX2015014036A (es) 2016-02-25
PL2981279T3 (pl) 2019-09-30
ES2714863T3 (es) 2019-05-30
RU2015146997A (ru) 2017-05-15
JP2016516756A (ja) 2016-06-09
BR112015025398A2 (pt) 2017-10-10
AU2014247979B2 (en) 2018-06-28
ZA201508010B (en) 2017-01-25
JP6449849B2 (ja) 2019-01-09
KR102191695B1 (ko) 2020-12-16
US9408886B2 (en) 2016-08-09
HUE043971T2 (hu) 2019-09-30
US10683328B2 (en) 2020-06-16
PT2981279T (pt) 2019-03-14
US20170121369A1 (en) 2017-05-04
HK1221159A1 (en) 2017-05-26
CN105517562A (zh) 2016-04-20
US10011636B2 (en) 2018-07-03
US20190119320A1 (en) 2019-04-25
KR20150140736A (ko) 2015-12-16
EP2981279A1 (en) 2016-02-10
CN105517562B (zh) 2018-12-28
US20210130403A1 (en) 2021-05-06
WO2014165853A1 (en) 2014-10-09
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
IL241937B (en) 2019-03-31
RU2015146997A3 (https=) 2018-03-13
MX363077B (es) 2019-03-07
EP2981279A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
WO2021098679A1 (zh) Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
US20110177155A1 (en) Methods of delivery of agents to leukocytes and endothelial cells
Jiang et al. Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy
US11466054B2 (en) Inhibitors of metastasis
AU2016363683B2 (en) Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
CA3102334A1 (en) Combination therapies comprising c/ebp alpha sarna
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
KR20210053242A (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
RU2679495C2 (ru) Связывающиеся с sdf1 нуклеиновые кислоты и их применение при лечении рака
WO2016071431A9 (en) A combination for cancer therapy
HK1221159B (en) Mareks inhibitor peptides for inhibiting metastasis
US20240075093A1 (en) Compositions and methods of treating a pi3k mediated disease
ES2338400B1 (es) Conjunto de moleculas antiangiogenicas y su uso.
TWI670079B (zh) 用於對抗具抗藥性癌症之組合物及方法
US12527818B2 (en) Platinum-based chemotherapy, mast binding agents, glucocorticoid receptor (GR) binding agents, and/or HSP90 binding agents for uses in treating cancer
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
NZ712955B2 (en) Inhibitors of metastasis
KR20250154429A (ko) 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포
CN119454908A (zh) 白细胞介素复合体及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241008

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241008

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128